In models of RSV immunization, TLR9 agonists formulated with formalin-inactivated RSV have increased immunogenicity while ameliorating pulmonary pathology and reducing airway hyperresponsiveness normally exacerbated by FI-RSV immunization (33, 34). This evidence concerns the gene TLR9 and airway hyperresponsiveness.